About asp isotopes inc - ASPI
ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.
ASPI At a Glance
ASP Isotopes, Inc.
601 Pennsylvania Avenue Northwest
Washington, District of Columbia 20004
| Phone | 1-202-756-2245 | Revenue | 4.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -32,333,581.00 | |
| Sector | Health Technology | 2024 Sales Growth | 857.039% | |
| Fiscal Year-end | 12 / 2025 | Employees | 136 | |
| View SEC Filings |
ASPI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 60.854 |
| Price to Book Ratio | 6.816 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.937 |
| Enterprise Value to Sales | 55.817 |
| Total Debt to Enterprise Value | 0.163 |
ASPI Efficiency
| Revenue/Employee | 30,472.25 |
| Income Per Employee | -237,746.919 |
| Receivables Turnover | 5.642 |
| Total Asset Turnover | 0.064 |
ASPI Liquidity
| Current Ratio | 9.314 |
| Quick Ratio | 9.305 |
| Cash Ratio | 8.768 |
ASPI Profitability
| Gross Margin | 38.599 |
| Operating Margin | -635.912 |
| Pretax Margin | -779.67 |
| Net Margin | -780.208 |
| Return on Assets | -49.638 |
| Return on Equity | -100.736 |
| Return on Total Capital | -37.753 |
| Return on Invested Capital | -63.654 |
ASPI Capital Structure
| Total Debt to Total Equity | 78.804 |
| Total Debt to Total Capital | 44.073 |
| Total Debt to Total Assets | 37.712 |
| Long-Term Debt to Equity | 75.416 |
| Long-Term Debt to Total Capital | 42.178 |